CHE trades 1.1% above Wall Street's consensus target of $475.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes CHE achieves its forward estimates and maintains a stable P/E multiple of 19.7x. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 7, 2026, Chemed Corporation (CHE) has a Wall Street consensus price target of $475.00, based on estimates from 9 covering analysts. With the stock currently trading at $480.50, this represents a potential downside of -1.1%. The company has a market capitalization of $6.57B.
Analyst price targets range from a low of $475.00 to a high of $475.00, representing a 0% spread in expectations. The median target of $475.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Hold, with 4 analysts rating the stock as a Buy or Strong Buy,5 rating it Hold, and 0 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, CHE trades at a trailing P/E of 26.1x and forward P/E of 19.7x. Analysts expect EPS to grow +28.1% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $572.19, with bear and bull scenarios of $360.48 and $753.92 respectively. Model confidence stands at 44/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
ADUSAddus HomeCare Corporation | $2.0B | $105.73 | $122.00 | +15.4% | Buy | 15.1x | 16 |
ENSGThe Ensign Group, Inc. | $9.7B | $166.83 | $222.33 | +33.3% | Buy | 22.1x | 13 |
SCIService Corporation International | $10.8B | $77.78 | $93.00 | +19.6% | Buy | 18.8x | 10 |
CSVCarriage Services, Inc. | $607M | $38.27 | $50.00 | +30.7% | Buy | 11.1x | 7 |
HCSGHealthcare Services Group, Inc. | $1.7B | $24.62 | $24.50 | -0.5% | Hold | 22.7x | 15 |
OPCHOption Care Health, Inc. | $3.3B | $21.36 | $31.22 | +46.2% | Buy | 11.6x | 14 |
UNHUnitedHealth Group Incorporated | $379.6B | $417.99 | $426.75 | +2.1% | Buy | 22.7x | 52 |
HUMHumana Inc. | $47.2B | $392.86 | $298.50 | -24.0% | Hold | 44.4x | 44 |
CVSCVS Health Corporation | $130.2B | $102.08 | $103.64 | +1.5% | Buy | 13.8x | 41 |
MCKMcKesson Corporation | $94.3B | $784.23 | $994.86 | +26.9% | Buy | 17.7x | 31 |
Quick answers to the most common questions about buying CHE stock.
Wall Street's consensus price target for CHE is $475, -1.1% from its current price of $480.5. The below-market target from 9 analysts suggests limited near-term appreciation.
CHE has a consensus rating of "Hold" based on 9 Wall Street analysts. The rating breakdown is mixed, with 5 Hold ratings making up the largest segment. The consensus 12-month price target of $475 implies -1.1% downside from current levels.
With a forward P/E of 19.7391x, CHE trades at a relatively low valuation. The consensus target of $475 implies -1.1% move, suggesting the market may be pricing in risks.
The most bullish Wall Street analyst has a price target of $475 for CHE, while the most conservative target is $475. The consensus of $475 represents the median expectation. Our quantitative valuation model projects a bull case target of $754 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
CHE is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 5 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CHE stock forecast based on 9 Wall Street analysts shows a consensus price target of $475, with estimates ranging from $475 (bear case) to $475 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $572, with bear/bull scenarios of $360/$754.
Our quantitative valuation model calculates CHE's fair value at $572 (base case), with a bear case of $360 and bull case of $754. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 44/100.
CHE trades at a forward P/E ratio of 19.7x based on next-twelve-months earnings estimates compared to a trailing P/E of 26.1x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Analysts are cautious on CHE, with 0 Sell ratings and a price target of $475 (-1.1% from current price). The "Hold" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CHE analyst price targets range from $475 to $475, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $475 consensus represents the middle ground. Our model's $360-$754 range provides an independent fundamental perspective.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.